News
Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action. It has a plasma elimination half-life of 12 hours and has been administered in a twice-daily dosing ...
The following is a summary of “Reversal of Factor Xa Inhibitor-Related Intracranial Hemorrhage: A Multicenter, Retrospective, Observational Study Comparing the Efficacy and Safety of Andexanet and ...
The OCEANIC-AF is comparing asundexian to Pfizer and Bristol-Myers Squibb’s widely-used oral Factor Xa inhibitor Eliquis (apixaban) in AF patients at risk of a stroke, to see how well they ...
Sepsis-induced coagulopathy (SIC) is a complication of sepsis tied to high mortality in patients. Anticoagulation using a coagulation factor IIa and Xa dual inhibitor might have the potential to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results